FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C.
20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October 2009
Commission File Number: 000-51440
CHINA MEDICAL
TECHNOLOGIES, INC.
(Translation of registrants name into English)
No. 24 Yong Chang North Road
Beijing
Economic-Technological Development Area
Beijing 100176
Peoples Republic of China
(Address of
principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by
check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
No
X
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
N/A
CHINA MEDICAL TECHNOLOGIES, INC.
Form 6-K
TABLE OF
CONTENTS
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
CHINA MEDICAL TECHNOLOGIES, INC.
|
|
|
By:
|
|
/s/ Takyung (Sam) Tsang
|
Name:
|
|
Takyung (Sam) Tsang
|
Title:
|
|
Chief Financial Officer
|
Date: October 2, 2009
3
Exhibit 99.1
China Medical Technologies Adjusts Conversion Rates of its US$150 Million
Convertible Notes and US$276 Million Convertible Notes
Beijing, September 30, 2009 - China Medical Technologies, Inc. (the Company) (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced
in-vitro diagnostic products, today announced adjustments to conversion rates of the Companys US$150 million outstanding 3.5% Convertible Senior Subordinated Notes due November 2011 (the US$150 million Convertible Notes) and the
Companys US$276 million outstanding 4.0% Convertible Senior Notes due August 2013 (the US$276 million Convertible Notes).
The adjustments are required, in accordance with the terms of the respective indentures governing the US$150 million Convertible Notes and US$276 million Convertible Notes, as a result of the Companys declaration of cash dividend of
US$0.055 per ordinary share, equivalent to US$0.55 per ADS for the fiscal year ended March 31, 2009.
US$150 million Convertible Notes
Conversion rate of the US$150 million Convertible Notes is adjusted from 31.7378 American Depositary Shares (ADSs) to 32.8322
ADSs for each US$1,000 original principal amount of the US$150 million Convertible Notes with reference to the closing market price of the Companys ADSs on September 29, 2009. The resulting conversion price for the US$150 million
Convertible Notes is reduced from US$31.51 to US$30.46. Assuming full conversion of the US$150 million Convertible Notes, additional 1,641,600 ordinary shares, equivalent to 164,160 ADSs will be issued by the Company as a result of the adjustment to
conversion rate. The adjustment became effective immediately prior to the opening of business on September 30, 2009.
US$276 million
Convertible Notes
Conversion rate of the US$276 million Convertible Notes is adjusted from 17.0068 ADSs to 17.5899 ADSs for each US$1,000
original principal amount of the US$276 million Convertible Notes with reference to the average closing market price of the Companys ADSs over a 10 consecutive trading day period from September 14, 2009 to September 25, 2009. The
resulting conversion price for the US$276 million Convertible Notes is reduced from US$58.80 to US$56.85. Assuming full conversion of the US$276 million Convertible Notes, additional 1,609,360 ordinary shares, equivalent to 160,936 ADSs will be
issued by the Company as a result of the adjustment to conversion rate. The adjustment became effective immediately prior to the opening of business on September 28, 2009.
About China Medical Technologies, Inc.
China Medical Technologies is a leading
China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance
(SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com.
Contact
Winnie Yam
Tel: +852-2511-9808
Email:
IR@chinameditech.com
4
Exhibit 99.2
China Medical Technologies Files its Annual Report on Form 20-F Containing its Audited
Consolidated Financial Statements for the Fiscal Year Ended March 31, 2009 with the SEC
Beijing, September 30, 2009 China Medical Technologies, Inc. (the Company) (Nasdaq: CMED), a leading China-based medical device
company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced the filing of its annual report on Form 20-F for the fiscal year ended March 31, 2009 with the U.S. Securities and Exchange Commission (the
SEC). The annual report, which contains its consolidated financial statements for the fiscal year ended March 31, 2009 audited by its new independent auditors, PricewaterhouseCoopers, and comparative consolidated financial
statements for the fiscal year ended March 31, 2008 audited by its former independent auditors, KPMG, can be accessed on the Companys investor relations website at http://ir.chinameditech.com. Shareholders can receive a hard copy of the
annual report free of charge by sending a request to IR@chinameditech.com.
The Company has recently made the following adjustments on its
previously reported unaudited quarterly and annual condensed consolidated statements of income which are setout below:
Reclassification of
expenses
Reclassification of sales and marketing expenses related to the costs of free ECLIA analyzers to cost of revenues
The Company considered that it was more appropriate to record the costs of ECLIA analyzers provided free of charge to the Companys
customers starting from April 2008 in the cost of revenues rather than sales and marketing expenses. The reclassification of the expenses to cost of revenues covered the respective unaudited quarterly consolidated income statement for the quarters
ended June 30, 2008, September 30, 2008, December 31, 2008, March 31, 2009 and June 30, 2009 and the unaudited annual consolidated income statement for the fiscal year ended March 31, 2009.
Reclassification of foreign exchange gain (loss) from general and administrative expenses to other income (expense)
The Company reclassified the foreign exchange gain (loss) from general and administrative expenses to other income (expense). The reclassification of the
gain (loss) to other income (expense) covered the respective unaudited quarterly consolidated income statement for the quarters ended June 30, 2008, September 30, 2008, December 31, 2008, March 31, 2009 and
June 30, 2009 and the unaudited annual consolidated income statement for the fiscal year ended March 31, 2009.
Recognition of
the full gain on the sale of the HIFU Business
The Company recently received a letter from Chengxuan International Ltd.
(Chengxuan), a major shareholder of the Company which is controlled and owned by the Companys Chairman and Chief Executive Officer, Mr. Xiaodong Wu. The letter notified the Company that Chengxuan withdrew its claim of
compensation of approximately US$15.5 million against the Company for the events subsequent to the purchase of the HIFU Business from the Company. As such, the Company considered that the previous deferral of the gain of approximately US$15.5
million on the sale of the HIFU Business has become unnecessary and has recorded the full gain on the sale in the unaudited quarterly consolidated income statement for the quarter ended December 31, 2008 and the unaudited annual consolidated
income statement for the fiscal year ended March 31, 2009.
5
The respective unaudited quarterly and annual condensed consolidated statements of income have been adjusted
and included in this press release.
About China Medical Technologies, Inc.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products
using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent
in situ
Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit
http://www.chinameditech.com
.
Contact
Winnie Yam
Tel: +852-2511-9808
Email:
IR@chinameditech.com
6
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
June 30, 2008
|
|
|
Adjustments
|
|
|
June 30, 2008
|
|
|
|
RMB000
As previously
reported on
September 1, 2009 (1)
|
|
|
RMB000
|
|
|
RMB000
As adjusted
|
|
|
|
|
|
Revenues
|
|
162,052
|
|
|
|
|
|
162,052
|
|
Cost of revenues (2)
|
|
(51,270
|
)
|
|
(3,444
|
)
|
|
(54,714
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
110,782
|
|
|
|
|
|
107,338
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(6,138
|
)
|
|
|
|
|
(6,138
|
)
|
Sales and marketing (2)
|
|
(11,285
|
)
|
|
3,444
|
|
|
(7,841
|
)
|
General and administrative (3)
|
|
(24,780
|
)
|
|
2,755
|
|
|
(22,025
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(42,203
|
)
|
|
|
|
|
(36,004
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
68,579
|
|
|
|
|
|
71,334
|
|
Interest income
|
|
3,997
|
|
|
|
|
|
3,997
|
|
Interest expense convertible notes
|
|
(16,285
|
)
|
|
|
|
|
(16,285
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(1,585
|
)
|
|
|
|
|
(1,585
|
)
|
Interest expense other
|
|
(1,145
|
)
|
|
|
|
|
(1,145
|
)
|
Other expense (3)
|
|
-
|
|
|
(2,755
|
)
|
|
(2,755
|
)
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
53,561
|
|
|
|
|
|
53,561
|
|
Income tax expense
|
|
(12,561
|
)
|
|
|
|
|
(12,561
|
)
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
41,000
|
|
|
|
|
|
41,000
|
|
Income from discontinued operation, net
|
|
32,377
|
|
|
|
|
|
32,377
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
73,377
|
|
|
-
|
|
|
73,377
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
As a result of the adoption of FSP APB14-1 effective April 2009, the Company adjusted interest expense for convertible notes in the unaudited condensed consolidated
statement of income for the three months ended June 30, 2008 retrospectively in accordance with U.S. GAAP.
|
(2)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(3)
|
The Company reclassified the foreign exchange loss from general and administrative expenses to other expense.
|
7
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
September 30, 2008
|
|
|
Adjustments
|
|
|
September 30, 2008
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
|
As previously
reported
|
|
|
|
|
|
As adjusted
|
|
|
|
|
|
Revenues
|
|
193,967
|
|
|
|
|
|
193,967
|
|
Cost of revenues (1)
|
|
(52,043
|
)
|
|
(5,265
|
)
|
|
(57,308
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
141,924
|
|
|
|
|
|
136,659
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(6,338
|
)
|
|
|
|
|
(6,338
|
)
|
Sales and marketing (1)
|
|
(16,515
|
)
|
|
5,265
|
|
|
(11,250
|
)
|
General and administrative (2)
|
|
(26,859
|
)
|
|
1,387
|
|
|
(25,472
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(49,712
|
)
|
|
|
|
|
(43,060
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
92,212
|
|
|
|
|
|
93,599
|
|
Interest income
|
|
10,301
|
|
|
|
|
|
10,301
|
|
Interest expense convertible notes
|
|
(18,410
|
)
|
|
|
|
|
(18,410
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(3,235
|
)
|
|
|
|
|
(3,235
|
)
|
Interest expense other
|
|
(1,145
|
)
|
|
|
|
|
(1,145
|
)
|
Other expense (2)
|
|
-
|
|
|
(1,387
|
)
|
|
(1,387
|
)
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
79,723
|
|
|
|
|
|
79,723
|
|
Income tax expense
|
|
(14,423
|
)
|
|
|
|
|
(14,423
|
)
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
65,300
|
|
|
|
|
|
65,300
|
|
Income from discontinued operation, net
|
|
52,432
|
|
|
|
|
|
52,432
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
117,732
|
|
|
-
|
|
|
117,732
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(2)
|
The Company reclassified the foreign exchange loss from general and administrative expenses to other expense.
|
8
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
December 31, 2008
|
|
|
Adjustments
|
|
|
December 31, 2008
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
|
As previously
reported
|
|
|
|
|
|
As adjusted
|
|
|
|
|
|
Revenues
|
|
225,296
|
|
|
|
|
|
225,296
|
|
Cost of revenues (1)
|
|
(55,818
|
)
|
|
(2,897
|
)
|
|
(58,715
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
169,478
|
|
|
|
|
|
166,581
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(8,304
|
)
|
|
|
|
|
(8,304
|
)
|
Acquired in-process research and development
|
|
(244,872
|
)
|
|
|
|
|
(244,872
|
)
|
Sales and marketing (1)
|
|
(14,565
|
)
|
|
2,897
|
|
|
(11,668
|
)
|
General and administrative (2) (3)
|
|
(38,115
|
)
|
|
8,554
|
|
|
(29,561
|
)
|
Amortization of SPR intangible assets (2)
|
|
-
|
|
|
(9,132
|
)
|
|
(9,132
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(305,856
|
)
|
|
|
|
|
(303,537
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
(136,378
|
)
|
|
|
|
|
(136,956
|
)
|
Interest income
|
|
12,448
|
|
|
|
|
|
12,448
|
|
Interest expense convertible notes
|
|
(27,856
|
)
|
|
|
|
|
(27,856
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(4,652
|
)
|
|
|
|
|
(4,652
|
)
|
Interest expense other
|
|
(1,165
|
)
|
|
|
|
|
(1,165
|
)
|
Other income (3)
|
|
-
|
|
|
578
|
|
|
578
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income taxes
|
|
(157,603
|
)
|
|
|
|
|
(157,603
|
)
|
Income tax expense
|
|
(13,915
|
)
|
|
|
|
|
(13,915
|
)
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
(171,518
|
)
|
|
|
|
|
(171,518
|
)
|
Income from and gain on sale of discontinued operation, net (4)
|
|
173,422
|
|
|
106,178
|
|
|
279,600
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
1,904
|
|
|
106,178
|
|
|
108,082
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(2)
|
The Company disclosed the amortization of SPR intangible assets separately from general and administrative expenses.
|
(3)
|
The Company reclassified the foreign exchange gain from general and administrative expenses to other income.
|
(4)
|
The Company recorded the full gain on the sale of the HIFU Business.
|
9
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
March 31, 2009
|
|
|
Adjustments
|
|
|
March 31, 2009
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
|
As previously
reported
|
|
|
|
|
|
As adjusted
|
|
|
|
|
|
Revenues
|
|
248,635
|
|
|
|
|
|
248,635
|
|
Cost of revenues (1)
|
|
(60,206
|
)
|
|
(1,628
|
)
|
|
(61,834
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
188,429
|
|
|
|
|
|
186,801
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(10,670
|
)
|
|
|
|
|
(10,670
|
)
|
Sales and marketing (1)
|
|
(13,591
|
)
|
|
1,628
|
|
|
(11,963
|
)
|
General and administrative (2) (3)
|
|
(48,085
|
)
|
|
27,547
|
|
|
(20,538
|
)
|
Amortization of SPR intangible assets (2)
|
|
-
|
|
|
(27,379
|
)
|
|
(27,379
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(72,346
|
)
|
|
|
|
|
(70,550
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
116,083
|
|
|
|
|
|
116,251
|
|
Interest income
|
|
5,608
|
|
|
|
|
|
5,608
|
|
Interest expense convertible notes
|
|
(27,840
|
)
|
|
|
|
|
(27,840
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(4,649
|
)
|
|
|
|
|
(4,649
|
)
|
Interest expense other
|
|
(785
|
)
|
|
|
|
|
(785
|
)
|
Other expense (3)
|
|
-
|
|
|
(168
|
)
|
|
(168
|
)
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
88,417
|
|
|
|
|
|
88,417
|
|
Income tax expense
|
|
(32,143
|
)
|
|
|
|
|
(32,143
|
)
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
56,274
|
|
|
|
|
|
56,274
|
|
Income from discontinued operation, net
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
56,274
|
|
|
-
|
|
|
56,274
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(2)
|
The Company disclosed the amortization of SPR intangible assets separately from general and administrative expenses.
|
(3)
|
The Company reclassified the foreign exchange loss from general and administrative expenses to other expense.
|
10
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
June 30, 2009
|
|
|
Adjustments
|
|
|
June 30, 2009
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
|
As previously
reported
|
|
|
|
|
|
As adjusted
|
|
|
|
|
|
Revenues
|
|
208,957
|
|
|
|
|
|
208,957
|
|
Cost of revenues (1)
|
|
(52,872
|
)
|
|
(2,541
|
)
|
|
(55,413
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
156,085
|
|
|
|
|
|
153,544
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(11,703
|
)
|
|
|
|
|
(11,703
|
)
|
Sales and marketing (1)
|
|
(13,411
|
)
|
|
2,541
|
|
|
(10,870
|
)
|
General and administrative (2) (3)
|
|
(74,366
|
)
|
|
27,412
|
|
|
(46,954
|
)
|
Amortization of SPR intangible assets (2)
|
|
-
|
|
|
(27,352
|
)
|
|
(27,352
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(99,480
|
)
|
|
|
|
|
(96,879
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
56,605
|
|
|
|
|
|
56,665
|
|
Interest income
|
|
2,773
|
|
|
|
|
|
2,773
|
|
Interest expense convertible notes
|
|
(35,432
|
)
|
|
|
|
|
(35,432
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(4,380
|
)
|
|
|
|
|
(4,380
|
)
|
Other income, net (3)
|
|
300
|
|
|
(60
|
)
|
|
240
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
19,866
|
|
|
|
|
|
19,866
|
|
Income tax expense
|
|
(16,919
|
)
|
|
|
|
|
(16,919
|
)
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
2,947
|
|
|
|
|
|
2,947
|
|
Income from discontinued operation, net
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
2,947
|
|
|
-
|
|
|
2,947
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(2)
|
The Company disclosed the amortization of SPR intangible assets separately from general and administrative expenses.
|
(3)
|
The Company reclassified the foreign exchange loss from general and administrative expenses to other income, net.
|
11
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
|
March 31, 2009
|
|
|
Adjustments
|
|
|
March 31, 2009
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
|
As previously
reported
|
|
|
|
|
|
As adjusted
|
|
|
|
|
|
Revenues
|
|
829,950
|
|
|
|
|
|
829,950
|
|
Cost of revenues (1)
|
|
(219,337
|
)
|
|
(13,234
|
)
|
|
(232,571
|
)
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
610,613
|
|
|
|
|
|
597,379
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
(31,450
|
)
|
|
|
|
|
(31,450
|
)
|
Acquired in-process research and development
|
|
(244,872
|
)
|
|
|
|
|
(244,872
|
)
|
Sales and marketing (1)
|
|
(55,956
|
)
|
|
13,234
|
|
|
(42,722
|
)
|
General and administrative (2) (3)
|
|
(137,839
|
)
|
|
40,243
|
|
|
(97,596
|
)
|
Amortization of SPR intangible assets (2)
|
|
-
|
|
|
(36,511
|
)
|
|
(36,511
|
)
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
(470,117
|
)
|
|
|
|
|
(453,151
|
)
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
140,496
|
|
|
|
|
|
144,228
|
|
Interest income
|
|
32,354
|
|
|
|
|
|
32,354
|
|
Interest expense convertible notes
|
|
(83,238
|
)
|
|
|
|
|
(83,238
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
(14,387
|
)
|
|
|
|
|
(14,387
|
)
|
Interest expense other
|
|
(4,240
|
)
|
|
|
|
|
(4,240
|
)
|
Other expense, net (3)
|
|
-
|
|
|
(3,732
|
)
|
|
(3,732
|
)
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
70,985
|
|
|
|
|
|
70,985
|
|
Income tax expense
|
|
(73,042
|
)
|
|
|
|
|
(73,042
|
)
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
(2,057
|
)
|
|
|
|
|
(2,057
|
)
|
Income from and gain on sale of discontinued operation, net (4)
|
|
258,231
|
|
|
106,178
|
|
|
364,409
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
256,174
|
|
|
106,178
|
|
|
362,352
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
The Company reclassified the costs of free ECLIA analyzers from sales and marketing expenses to cost of revenues.
|
(2)
|
The Company disclosed the amortization of SPR intangible assets separately from general and administrative expenses.
|
(3)
|
The Company reclassified the foreign exchange loss, net from general and administrative expenses to other expense, net.
|
(4)
|
The Company recorded the full gain on the sale of the HIFU Business.
|
12
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Sep 2024 to Oct 2024
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Oct 2023 to Oct 2024